Northwest Biotherapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 31.52 | -100% | 3.71 | -100% |
| P/S |
|
456.31 | 3.23 | 14028.19% |
|
|
| P/BV |
|
-13.4 | 3.36 | -498.95% |
|
|
| P/FCF |
|
0 | 21.22 | -100% |
|
|
| Ev/Ebitda |
|
-9.03 | 9.93 | -190.9% |
|
|
| Ev/S |
|
476.33 | 1.88 | 25175.09% |
|
|
| Ev/FCF |
|
-16.12 | 19.91 | -180.98% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-5791.09 | 24.35 | -23880.09% | -6890.58 | -15.96% |
| ROE |
|
95.17 | 13.11 | 625.79% |
|
|
| ROA |
|
-224.65 | 6.09 | -3786.21% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
-3240.11 | 12.44 | -26153.57% |
|
|
| ROCE |
|
0 | 14.35 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.4184 | 6.21 | -106.73% | -0.061 | +586.02% |
| Nеt Debt/Ebitda |
|
-0.3966 | -5.72 | -93.07% |
|
|
| Debt/Ratio |
|
1.46 | 0.213 | 587.3% |
|
|
| Debt/Equity |
|
0 | 12.49 | -100% |
|
|
| Debt/Net Income |
|
-0.6516 | 15.07 | -104.32% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.76 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.7783 | -100% |
|
|
| Average dividend growth |
|
0 | -269.81 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.8 | -100% |
|
|
| Average percentage for payments |
|
0 | 246.95 | -100% |
|
|
| Difference from average difference in sector |
|
-1.76 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-19.5 | 132.71 | -114.69% | ||
| Growth impulse Ebitda in 5 years |
|
296.2 | 100.7 | 194.14% | ||
| Growth impulse Net Income in 5 years |
|
208.37 | 116.53 | 78.81% | ||
| Growth impulse FCF in 5 years |
|
77.25 | 88.28 | -12.49% | ||
| Growth impulse EPS in 5 years |
|
61.38 | 217.84 | -71.82% |
IP Score
4.09/10
